





		EMLc	Codes ATC: J01DD04
Indication	Endophthalmitis	Code ICD11: 9C21	
INN	Ceftriaxone		
Type de médicament	Chemical agent		
Groupes d'antibiotiques	 WATCH		
Type de liste	Liste de base (EML) (EMLc)		
Additional notes	Do not administer with calcium and avoid in infants with hyperbilirubinaemia.		
Formulations	Parenteral > Locoregional injections > Intravitreal: 250 mg in vial powder for injection (as sodium salt) ; 500 mg in vial powder for injection (as sodium salt) ; 1 g in vial powder for injection (as sodium salt) ; 2 g in vial powder for injection (as sodium salt) (EML)		
Historique des statuts LME	Ajouté pour la première fois en 2021 (TRS 1035) Modifié en 2023 (TRS 1049)		
Sexe	Tous		
Âge	Aussi recommandé pour les enfants		
Limite d'âge	> 41 weeks corrected gestational age		
Équivalence thérapeutique	La recommandation concerne ce médicament spécifique		
Renseignements sur le brevet	Patents have expired in most jurisdictions Lire la suite sur les brevets. 		
Wikipédia	Ceftriaxone 		
DrugBank	Ceftriaxone 		

Recommandation du comité d'experts

In consideration of the review of the age appropriateness of formulations of medicines on the EMLc, and the comparison report of the EML versus EMLc, the Expert Committee recommended changes to the EMLc for addition of new, age-appropriate formulations and strengths of existing essential medicines, deletion of unavailable or age-inappropriate formulations and strengths, and other listing modifications as proposed in the application. The Committee also endorsed the proposals for further review of the public health relevance and evidence for specific medicines for use in children for potential future consideration for inclusion on the EMLc. The Committee noted and welcomed the ongoing review being coordinated by the Secretariat for the remaining sections of the EMLc for consideration by the 2025 Expert Committee. As a result of the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended: - the addition of a new strength formulation of ceftriaxone (powder for injection: 500 mg (as sodium) in vial) to the EML and EMLc. - the addition of new strength formulations of IV vancomycin (500 mg, 1 g (as hydrochloride) on the EMLc.

Recommandations de la LME : Endophthalmitis

Premier choix

Second choix

ceftazidime

co-prescrite avec [vancomycin](#)

ceftriaxone

co-prescrite avec [vancomycin](#)

